<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39359733</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 spike protein induces the cytokine release syndrome by stimulating T cells to produce more IL-2.</ArticleTitle><Pagination><StartPage>1444643</StartPage><MedlinePgn>1444643</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1444643</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1444643</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Cytokine release syndrome (CRS) is one of the leading causes of mortality in patients with COVID-19 caused by the SARS-CoV-2 coronavirus. However, the mechanism of CRS induced by SARS-CoV-2 is vague.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Using spike protein combined with IL-2, IFN-γ, and TNF-α to stimulate human peripheral blood mononuclear cells (PBMCs) to secrete CRS-related cytokines, the content of cytokines in the supernatant was detected, and the effects of NK, T, and monocytes were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">This study shows that dendritic cells loaded with spike protein of SARS-CoV-2 stimulate T cells to release much more interleukin-2 (IL-2,) which subsequently cooperates with spike protein to facilitate PBMCs to release IL-1β, IL-6, and IL-8. These effects are achieved via IL-2 stimulation of NK cells to release tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), as well as T cells to release IFN-γ Mechanistically, IFN-γ and TNF-α enhance the transcription of CD40, and the interaction of CD40 and its ligand stabilizes the membrane expression of toll-like receptor 4 (TLR4) that serves as a receptor of spike protein on the surface of monocytes. As a result, there is a constant interaction between spike protein and TLR4, leading to continuous activation of nuclear factor-κ-gene binding (NF-κB). Furthermore, TNF-α also activates NF-κB signaling in monocytes, which further cooperates with IFN-γ and spike protein to modulate NF-κB-dependent transcription of CRS-related inflammatory cytokines.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Targeting TNF-α/IFN-γ in combination with TLR4 may represent a promising therapeutic approach for alleviating CRS in individuals with COVID-19.</AbstractText><CopyrightInformation>Copyright © 2024 Niu, Liang, Chen, Zhu, Zhou, Chen, Qian, Wang, Li, Zhou and Cui.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Center of Future Science, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yongchong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Naifei</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yufeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Center of Future Science, Jilin University, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Jiuwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="Y">Interleukin-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="Y">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="Y">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD40</Keyword><Keyword MajorTopicYN="N">NF-κB</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cytokine release syndrome</Keyword><Keyword MajorTopicYN="N">monocyte</Keyword><Keyword MajorTopicYN="N">spike protein</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39359733</ArticleId><ArticleId IdType="pmc">PMC11445618</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1444643</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-coV-2 and COVID-19. Nat Rev Microbiol. (2021) 19:141–54. doi: 10.1038/s41579-020-00459-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Perlman S. COVID-19: inflammatory profile. Annu Rev Med. (2022) 73:65–80. doi: 10.1146/annurev-med-042220-012417</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042220-012417</ArticleId><ArticleId IdType="pubmed">34437814</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorey TM, Ziegler CGK, Heimberg G, Normand R, Yang Y, Segerstolpe A, et al. . COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. (2021) 595:107–13. doi: 10.1038/s41586-021-03570-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03570-8</ArticleId><ArticleId IdType="pmc">PMC8919505</ArticleId><ArticleId IdType="pubmed">33915569</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao N, Nie M, Pang H, Wang B, Hu J, Meng X, et al. . Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. Nat Commun. (2021) 12:1618. doi: 10.1038/s41467-021-21907-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21907-9</ArticleId><ArticleId IdType="pmc">PMC7955129</ArticleId><ArticleId IdType="pubmed">33712622</ArticleId></ArticleIdList></Reference><Reference><Citation>Que Y, Hu C, Wan K, Hu P, Wang R, Luo J, et al. . Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol. (2022) 41:217–30. doi: 10.1080/08830185.2021.1884248</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2021.1884248</ArticleId><ArticleId IdType="pmc">PMC7919105</ArticleId><ArticleId IdType="pubmed">33616462</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4. doi: 10.1016/S0140-6736(20)30628-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. . Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. (2020) 27:992–1000 e3. doi: 10.1016/j.chom.2020.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S, Dey A, Bandhyopadhyay S, Uversky VN, Maulik U. Understanding structural malleability of the SARS-CoV-2 proteins and relation to the comorbidities. Brief Bioinform. (2021) 22:bbab232. doi: 10.1093/bib/bbab232</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab232</ArticleId><ArticleId IdType="pubmed">34143202</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. (2022) 23:3–20. doi: 10.1038/s41580-021-00418-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Kuang M, Li J, Zhu L, Jia Z, Guo X, et al. . Publisher Correction: SARS-CoV-2 spike protein interacts with and activates TLR4. Cell Res. (2021) 31:825. doi: 10.1038/s41422-021-00501-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00501-0</ArticleId><ArticleId IdType="pmc">PMC8077189</ArticleId><ArticleId IdType="pubmed">33907310</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Kuang M, Li J, Zhu L, Jia Z, Guo X, et al. . SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. (2021) 31:818–20. doi: 10.1038/s41422-021-00495-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00495-9</ArticleId><ArticleId IdType="pmc">PMC7975240</ArticleId><ArticleId IdType="pubmed">33742149</ArticleId></ArticleIdList></Reference><Reference><Citation>To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. . Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. (2020) 20:565–74. doi: 10.1016/S1473-3099(20)30196-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30196-1</ArticleId><ArticleId IdType="pmc">PMC7158907</ArticleId><ArticleId IdType="pubmed">32213337</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. . SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. (2020) 81:357–71. doi: 10.1016/j.jinf.2020.06.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.06.067</ArticleId><ArticleId IdType="pmc">PMC7323671</ArticleId><ArticleId IdType="pubmed">32615199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. (2020) 20:411–2. doi: 10.1016/S1473-3099(20)30113-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30113-4</ArticleId><ArticleId IdType="pmc">PMC7128099</ArticleId><ArticleId IdType="pubmed">32105638</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajjela BK, Zhou MM. Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling. Drug Discovery Today. (2022) 27:390–400. doi: 10.1016/j.drudis.2021.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.10.016</ArticleId><ArticleId IdType="pmc">PMC8553370</ArticleId><ArticleId IdType="pubmed">34743903</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. (2020) 26:842–4. doi: 10.1038/s41591-020-0901-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y, Tang F. SARS-CoV-2-mediated immune system activation and potential application in immunotherapy. Med Res Rev. (2021) 41:1167–94. doi: 10.1002/med.21756</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21756</ArticleId><ArticleId IdType="pubmed">33185926</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. . Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. (2020) 55:102763. doi: 10.1016/j.ebiom.2020.102763</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102763</ArticleId><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari H, Tabrizi R, Lankarani KB, Aria H, Vakili S, Asadian F, et al. . The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Life Sci. (2020) 258:118167. doi: 10.1016/j.lfs.2020.118167</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118167</ArticleId><ArticleId IdType="pmc">PMC7387997</ArticleId><ArticleId IdType="pubmed">32735885</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. (2012) 12:180–90. doi: 10.1038/nri3156</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3156</ArticleId><ArticleId IdType="pubmed">22343569</ArticleId></ArticleIdList></Reference><Reference><Citation>van Haelst Pisani C, Kovach JS, Kita H, Leiferman KM, Gleich GJ, Silver JE, et al. . Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood. (1991) 78:1538–44. doi: 10.1182/blood.V78.6.1538.1538</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V78.6.1538.1538</ArticleId><ArticleId IdType="pubmed">1884020</ArticleId></ArticleIdList></Reference><Reference><Citation>Case R, Ramaniuk A, Martin P, Simpson PJ, Harden C, Ataya A. Systemic capillary leak syndrome secondary to coronavirus disease 2019. Chest. (2020) 158:e267–e8. doi: 10.1016/j.chest.2020.06.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.06.049</ArticleId><ArticleId IdType="pmc">PMC7332444</ArticleId><ArticleId IdType="pubmed">32622823</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. (2020) 111:102452. doi: 10.1016/j.jaut.2020.102452</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102452</ArticleId><ArticleId IdType="pmc">PMC7151347</ArticleId><ArticleId IdType="pubmed">32291137</ArticleId></ArticleIdList></Reference><Reference><Citation>Smoke SM, Raja K, Hilden P, Daniel NM. Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study. Int J Antimicrob Agents. (2021) 57:106265. doi: 10.1016/j.ijantimicag.2020.106265</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106265</ArticleId><ArticleId IdType="pmc">PMC7834231</ArticleId><ArticleId IdType="pubmed">33338559</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Bona D, Cippitelli M, Fionda C, Camma C, Licata A, Santoni A, et al. . Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol. (2006) 45:271–9. doi: 10.1016/j.jhep.2006.01.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2006.01.037</ArticleId><ArticleId IdType="pubmed">16595158</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Connell D, Bouazza B, Kokalari B, Amrani Y, Khatib A, Ganther JD, et al. . IFN-gamma-induced JAK/STAT, but not NF-kappaB, signaling pathway is insensitive to glucocorticoid in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. (2015) 309:L348–59. doi: 10.1152/ajplung.00099.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00099.2015</ArticleId><ArticleId IdType="pmc">PMC4538237</ArticleId><ArticleId IdType="pubmed">26092996</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Cui H, Li S, Li X, Guo H, Nandakumar KS, et al. . Kaempferol modulates IFN-gamma induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions. Int Immunopharmacol. (2023) 114:109585. doi: 10.1016/j.intimp.2022.109585</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109585</ArticleId><ArticleId IdType="pubmed">36527884</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsyth CB, Zhang L, Bhushan A, Swanson B, Zhang L, Mamede JI, et al. . The SARS-coV-2 S1 spike protein promotes MAPK and NF-kB activation in human lung cells and inflammatory cytokine production in human lung and intestinal epithelial cells. Microorganisms. (2022) 10:1996. doi: 10.3390/microorganisms10101996</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms10101996</ArticleId><ArticleId IdType="pmc">PMC9607240</ArticleId><ArticleId IdType="pubmed">36296272</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Griw MA, Salter MG, Wood IC. Blocking of NF−kB/p38 MAPK pathways mitigates oligodendrocyte pathology in a model of neonatal white matter injury. Acta Neurobiol Exp (Wars). (2022) 82:52–64. doi: 10.55782/ane-2022-005</Citation><ArticleIdList><ArticleId IdType="doi">10.55782/ane-2022-005</ArticleId><ArticleId IdType="pubmed">35451423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Kim JY. Anti-CD14 antibody reduces LPS responsiveness via TLR4 internalization in human monocytes. Mol Immunol. (2014) 57:210–5. doi: 10.1016/j.molimm.2013.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2013.09.009</ArticleId><ArticleId IdType="pubmed">24172224</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatematsu M, Yoshida R, Morioka Y, Ishii N, Funami K, Watanabe A, et al. . Raftlin controls lipopolysaccharide-induced TLR4 internalization and TICAM-1 signaling in a cell type-specific manner. J Immunol. (2016) 196:3865–76. doi: 10.4049/jimmunol.1501734</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501734</ArticleId><ArticleId IdType="pubmed">27022195</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Luo J, Chen D, Xu H, Shi H, Jing X, et al. . CD36 regulates lipopolysaccharide-induced signaling pathways and mediates the internalization of Escherichia coli in cooperation with TLR4 in goat mammary gland epithelial cells. Sci Rep. (2016) 6:23132. doi: 10.1038/srep23132</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23132</ArticleId><ArticleId IdType="pmc">PMC4791551</ArticleId><ArticleId IdType="pubmed">26976286</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhang M, Zhong H, Xie N, Wang Y, Ding S, et al. . LncRNA SNHG16 regulates RAS and NF-kappaB pathway-mediated NLRP3 inflammasome activation to aggravate diabetes nephropathy through stabilizing TLR4. Acta Diabetol. (2023) 60:563–77. doi: 10.1007/s00592-022-02021-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-022-02021-8</ArticleId><ArticleId IdType="pubmed">36658449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. (2021) 78:1233–61. doi: 10.1007/s00018-020-03656-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-020-03656-y</ArticleId><ArticleId IdType="pmc">PMC7904555</ArticleId><ArticleId IdType="pubmed">33057840</ArticleId></ArticleIdList></Reference><Reference><Citation>Aerbajinai W, Lee K, Chin K, Rodgers GP. Glia maturation factor-gamma negatively modulates TLR4 signaling by facilitating TLR4 endocytic trafficking in macrophages. J Immunol. (2013) 190:6093–103. doi: 10.4049/jimmunol.1203048</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1203048</ArticleId><ArticleId IdType="pmc">PMC3679304</ArticleId><ArticleId IdType="pubmed">23677465</ArticleId></ArticleIdList></Reference><Reference><Citation>Frleta D, Noelle RJ, Wade WF. CD40-mediated up-regulation of Toll-like receptor 4-MD2 complex on the surface of murine dendritic cells. J Leukoc Biol. (2003) 74:1064–73. doi: 10.1189/jlb.0203062</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0203062</ArticleId><ArticleId IdType="pubmed">12960264</ArticleId></ArticleIdList></Reference><Reference><Citation>Yongzhi X. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue. Emerg Microbes Infect. (2021) 10:266–76. doi: 10.1080/22221751.2021.1884503</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1884503</ArticleId><ArticleId IdType="pmc">PMC7894425</ArticleId><ArticleId IdType="pubmed">33522893</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. (2022) 23:186–93. doi: 10.1038/s41590-021-01122-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. . Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. (2020) 369:m1443. doi: 10.1136/bmj.m1443</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1443</ArticleId><ArticleId IdType="pmc">PMC7190077</ArticleId><ArticleId IdType="pubmed">32317267</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariharan A, Hakeem AR, Radhakrishnan S, Reddy MS, Rela M. The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients. Inflammopharmacology. (2021) 29:91–100. doi: 10.1007/s10787-020-00773-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00773-9</ArticleId><ArticleId IdType="pmc">PMC7648206</ArticleId><ArticleId IdType="pubmed">33159646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircheis R, Haasbach E, Lueftenegger D, Heyken WT, Ocker M, Planz O. NF-kappaB pathway as a potential target for treatment of critical stage COVID-19 patients. Front Immunol. (2020) 11:598444. doi: 10.3389/fimmu.2020.598444</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.598444</ArticleId><ArticleId IdType="pmc">PMC7759159</ArticleId><ArticleId IdType="pubmed">33362782</ArticleId></ArticleIdList></Reference><Reference><Citation>Manik M, Singh RK. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J Med Virol. (2022) 94:869–77. doi: 10.1002/jmv.27405</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27405</ArticleId><ArticleId IdType="pmc">PMC8662021</ArticleId><ArticleId IdType="pubmed">34672376</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandao SCS, Ramos JOX, Dompieri LT, Godoi E, Figueiredo JL, Sarinho ESC, et al. . Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? Cytokine Growth Factor Rev. (2021) 58:102–10. doi: 10.1016/j.cytogfr.2020.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.09.002</ArticleId><ArticleId IdType="pmc">PMC7505161</ArticleId><ArticleId IdType="pubmed">32988728</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte C. Possible link between SARS-coV-2 infection and parkinson’s disease: the role of toll-like receptor 4. Int J Mol Sci. (2021) 22:7135. doi: 10.3390/ijms22137135</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22137135</ArticleId><ArticleId IdType="pmc">PMC8269350</ArticleId><ArticleId IdType="pubmed">34281186</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo X, Zhang X, Yu C, Cheng E, Zhang Q, Dunbar KB, et al. . Aspirin prevents NF-kappaB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett’s oesophagus. Gut. (2018) 67:606–15. doi: 10.1136/gutjnl-2016-313584</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313584</ArticleId><ArticleId IdType="pmc">PMC5656558</ArticleId><ArticleId IdType="pubmed">28442495</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D, Zhong L, Duan T, Zhang RH, Wang X, Wang G, et al. . Aspirin suppresses the growth and metastasis of osteosarcoma through the NF-kappaB pathway. Clin Cancer Res. (2015) 21:5349–59. doi: 10.1158/1078-0432.CCR-15-0198</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0198</ArticleId><ArticleId IdType="pubmed">26202947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol. (2008) 9:361–8. doi: 10.1038/ni1569</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1569</ArticleId><ArticleId IdType="pmc">PMC4112825</ArticleId><ArticleId IdType="pubmed">18297073</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C, Wang H, Zhang M, Mustafa S, Wang Y, Li H, et al. . TLR4 biased small molecule modulators. Pharmacol Ther. (2021) 228:107918. doi: 10.1016/j.pharmthera.2021.107918</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2021.107918</ArticleId><ArticleId IdType="pubmed">34171331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangloff M. Different dimerisation mode for TLR4 upon endosomal acidification? Trends Biochem Sci. (2012) 37:92–8. doi: 10.1016/j.tibs.2011.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2011.11.003</ArticleId><ArticleId IdType="pmc">PMC3323831</ArticleId><ArticleId IdType="pubmed">22196451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Qin H, Benveniste EN. Simvastatin inhibits IFN-gamma-induced CD40 gene expression by suppressing STAT-1alpha. J Leukoc Biol. (2007) 82:436–47. doi: 10.1189/jlb.1206739</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1206739</ArticleId><ArticleId IdType="pubmed">17507688</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheny M, Maleque N, Channell N, Eisch AR, Auld SC, Banerji A, et al. . Severe exacerbations of systemic capillary leak syndrome after COVID-19 vaccination: A case series. Ann Intern Med. (2021) 174:1476–8. doi: 10.7326/L21-0250</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/L21-0250</ArticleId><ArticleId IdType="pmc">PMC8252024</ArticleId><ArticleId IdType="pubmed">34125573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Li Q, Wang H, Du X, Lai Q, Li X, et al. . TNF-alpha: A serological marker for evaluating the severity of hippocampal sclerosis in medial temporal lobe epilepsy? J Clin Neurosci. (2024) 123:123–9. doi: 10.1016/j.jocn.2024.03.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2024.03.030</ArticleId><ArticleId IdType="pubmed">38569383</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, He L, Jin Z, Lu G, Yu S, Hu L, et al. . Immune dysfunction-associated elevated RDW, APACHE-II, and SOFA scores were a possible cause of 28-day mortality in sepsis patients. Infect Drug Resist. (2024) 17:1199–213. doi: 10.2147/IDR.S442169</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S442169</ArticleId><ArticleId IdType="pmc">PMC10981425</ArticleId><ArticleId IdType="pubmed">38560707</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Chan E, Yin Y, Ghosh CC, Wisch L, Nelson C, et al. . Inflammatory markers of the systemic capillary leak syndrome (Clarkson disease). J Clin Cell Immunol. (2014) 5:1000213. doi: 10.4172/2155-9899.1000213</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155-9899.1000213</ArticleId><ArticleId IdType="pmc">PMC4232957</ArticleId><ArticleId IdType="pubmed">25405070</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai GH, Zhang W, Xiang Z, He LZ, Wang WW, Wu J, et al. . Diagnostic value of sIL-2R, TNF-alpha and PCT for sepsis infection in patients with closed abdominal injury complicated with severe multiple abdominal injuries. Front Immunol. (2021) 12:741268. doi: 10.3389/fimmu.2021.741268</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.741268</ArticleId><ArticleId IdType="pmc">PMC8569904</ArticleId><ArticleId IdType="pubmed">34745113</ArticleId></ArticleIdList></Reference><Reference><Citation>Falck-Jones S, Osterberg B, Smed-Sorensen A. Respiratory and systemic monocytes, dendritic cells, and myeloid-derived suppressor cells in COVID-19: Implications for disease severity. J Intern Med. (2022) 293:130–43. doi: 10.1111/joim.13559</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13559</ArticleId><ArticleId IdType="pmc">PMC9538918</ArticleId><ArticleId IdType="pubmed">35996885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Qiu F, Deng C, Li J, Huang Y, Wu Z, et al. . Integrating single-cell sequencing data with GWAS summary statistics reveals CD16+monocytes and memory CD8+T cells involved in severe COVID-19. Genome Med. (2022) 14:16. doi: 10.1186/s13073-022-01021-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-022-01021-1</ArticleId><ArticleId IdType="pmc">PMC8851814</ArticleId><ArticleId IdType="pubmed">35172892</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. (2020) 20:355–62. doi: 10.1038/s41577-020-0331-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0331-4</ArticleId><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pence BD. Severe COVID-19 and aging: are monocytes the key? Geroscience. (2020) 42:1051–61. doi: 10.1007/s11357-020-00213-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-020-00213-0</ArticleId><ArticleId IdType="pmc">PMC7299454</ArticleId><ArticleId IdType="pubmed">32556942</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>